At the moment the drug itself is given in doses that the human body doesn't normally react too much to but when the treatment is given once a month the rate of the disease decline has been shown to be slowed down by at least 15 per cent.

A major breakthrough is that there is an entire group of molecules with the ability to stop the onset of Alzheimer’s and have a therapeutic effect.

The study was done looking at the molecular pathway of a group of molecules called c-AMPs or non-selective -amino-3-hydroxy-5-methylisoxazole-3-carboxylic acid.

These molecules are currently used at an Alzheimer’s disease clinic so they can be used for the development and testing of drugs that can treat the disease.

Although a direct molecular mimic has not been found so far, researchers believe that in the future, these molecules may be used for treating Parkinson’s disease, cancer, and other diseases.

In addition to the research findings, it has been found that this molecular mimic is in essence a type of drug and is an effective treatment in patients.

In humans, the use of these molecules are being shown to have an impact in the prevention and treatment of the Alzheimer’s disease.

There are two types of c-AMPs. One can be used to treat brain tumours and one to treat Alzheimer’s disease. There are also anti-bio-tumour drugs that are currently being explored. C-AMPs can inhibit the formation of tumours and also inhibit the process of nerve cells dieing. These are two types of drugs. The compound in the study that is an anti-bio-tumour treatment called tSINP is a specific type of mAb. This is a very potent anti-bio-tumour treatment. I guess it only works on tumours that are in the brain so this doesn’t work as effectively against tumours in the heart and lung or on other parts of the body. It has also been shown to help prevent the death of mitochondria from damage from a number of various types of disease. So the effect is very much in its own right. One of these is the form of the molecule that is being used in this study. It is not yet known what the therapeutic effect is for the neurodegenerative disease which is known as Alzheimer’s. However, the anti-bio-tumour drug tSINP is currently being trialled in humans.

So what effect will these molecules have on the dementia and the death of neurons of the brain and are they even capable of stopping the disease? It is very likely that even the very early stage will prove to be a significant hurdle for these mechanisms. The next few years will continue to unfold and we will watch how well this molecule helps us slow down the progression of the disease. At the moment the drug itself is given in doses that the human body doesn’t normally react too much to but when the treatment is given once a month the rate of the disease decline has been shown to be slowed down by at least 15 per cent. More research is required, this is just the beginning of the research on these drugs.

This study adds to the body of research we have been conducting looking at mechanisms that interact with c-AMP which also have shown to speed up the progress of Alzheimer’s in animal models. If this new study is the beginning of a breakthrough against Alzheimer’s, then I feel that the pharmaceutical companies would benefit greatly from investing in this and testing this as much as they can.

Last month, the Wall Street Journal reported Several countries, including China and Russia, are also expanding internet controls to block 'illegal content,' even as activists and politicians around the world continue to demand web services take responsibility for the actions of their users. The authors of the report, Public Health at an Unmeasured Crossroads The Surprising Rise and Fall of Life Expectancy in the United States, examined several variables including poverty, population density, income, and education.
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×